Creation and assessment of a CT-radiomics framework for diagnosing lung cancer linked to cystic airspaces: a multicenter investigation - Top-Institutions - MDSpire

Creation and assessment of a CT-radiomics framework for diagnosing lung cancer linked to cystic airspaces: a multicenter investigation

  • By

  • Jiangshan Ai

  • Hengyan Li

  • Man Wang

  • Lianzheng Zhao

  • Yuanyong Wang

  • Shiwen Ai

  • December 9, 2025

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Thoracic Oncology
    • Radiology
    • Medical Imaging Informatics

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Thoracic Oncology
    • Radiology
    • Computational Imaging

  • #3

    Brigham and Women's Hospital
    Brigham and Women's Hospital

    Boston, MA

    Key Differentiators

    • Radiology
    • Pulmonary Medicine
    • Oncology

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Thoracic Radiology
    • Oncology
    • Biomedical Imaging

  • #5

    National Cancer Institute (NCI)
    National Cancer Institute (NCI)

    Bethesda, MD

    Key Differentiators

    • Cancer Research
    • Radiology
    • Biomedical Informatics

Original Source(s)

Creation and assessment of a CT-radiomics framework for diagnosing lung cancer linked to cystic airspaces: a multicenter investigation

  • by Jiangshan Ai, Hengyan Li, Man Wang, Lianzheng Zhao, Yuanyong Wang, Shiwen Ai

  • December 9, 2025

Related Content

Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy

An ASCO preview: What to watch for at cancer research’s big meeting

An LDH-based prognostic model for extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy and consolidative thoracic radiotherapy